探讨 SGLT2 抑制剂治疗糖尿病心肌病的机制。
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms.
机构信息
Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Key Laboratory of Medical Electrophysiology, Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, Sichuan, China.
Department of Cardiovascular Surgery, Metabolic Vascular Diseases Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
出版信息
Cardiovasc Diabetol. 2023 Apr 13;22(1):86. doi: 10.1186/s12933-023-01816-5.
Among the complications of diabetes, cardiovascular events and cardiac insufficiency are considered two of the most important causes of death. Experimental and clinical evidence supports the effectiveness of SGLT2i for improving cardiac dysfunction. SGLT2i treatment benefits metabolism, microcirculation, mitochondrial function, fibrosis, oxidative stress, endoplasmic reticulum stress, programmed cell death, autophagy, and the intestinal flora, which are involved in diabetic cardiomyopathy. This review summarizes the current knowledge of the mechanisms of SGLT2i for the treatment of diabetic cardiomyopathy.
在糖尿病的并发症中，心血管事件和心功能不全被认为是最重要的死亡原因之一。实验和临床证据支持 SGLT2i 改善心功能障碍的有效性。SGLT2i 治疗有益于代谢、微循环、线粒体功能、纤维化、氧化应激、内质网应激、程序性细胞死亡、自噬和肠道菌群，这些都与糖尿病心肌病有关。本文综述了 SGLT2i 治疗糖尿病心肌病的作用机制的最新知识。
Zotero 插件